RxDoctor Payments Data

Kristopher Wise

Primary Care · Saginaw, MINPI 1679230148

Payments from drug & device makers

$391in general payments, 2019–2025

Across 21 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62
  • Organon$62
  • Johnson & Johnson$41
  • Dexcom, Inc.$39
  • AstraZeneca$32
  • Exact Sciences$26
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$391 in reported general payments places this provider in the 50th percentile of 292 primary care providers in Michigan.

See all primary care providers in Michigan

Medicare billing

Part B allowed, 2024
$336
Medicare patients
20
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol26$41,850
JardianceEmpagliflozin37$37,695
OzempicSemaglutide37$36,460
TrulicityDulaglutide39$36,254
JanuviaSitagliptin Phosphate43$35,832
EliquisApixaban30$28,462
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,850
XareltoRivaroxaban12$20,769
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$18,016
MounjaroTirzepatide17$16,403
Spiriva HandihalerTiotropium Bromide12$13,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,803
Incruse ElliptaUmeclidinium Bromide13$5,920
Albuterol Sulfate HfaAlbuterol Sulfate109$3,606
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$19$52,65756 claims
AstraZenecaFarxiga$32$41,85026 claims
Novo NordiskOzempic$18$36,46037 claims
Johnson & JohnsonXarelto$41$20,76912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 292 primary care providers in Michigan.

Other primary care in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →